泰利福 Rüsch™ EZ-Blocker™一次性使用双侧支气管堵塞器获 NMPA 批准,...
http://www.qm120.com2025-08-08 17:30:09 来源:全民健康网作者:美通社 PR Newswire
宾夕法尼亚州韦恩和上海2025年8月7日 /美通社/ -- 泰利福公司(NYSE: TFX),全球领先的医疗技术公司,今日宣布其旗下Rüsch™ EZ-Blocker™ 一次性使用双侧支气管堵塞器已成功通过中国国家药品监督管理局(NMPA)的严格审评审批,并正式取得医疗器械注册证(注册证编号:国械注进20252080316)。这不仅是泰利福中国产品组合的一次重要升级优化,更为公司在华业务的增长注入强劲动力。
泰利福Rüsch™ EZ-Blocker™一次性使用双侧支气管堵塞器
泰利福中国始终致力于为全球医疗市场提供创新的医疗解决方案,此次 Rüsch™ EZ-Blocker™一次性使用双侧支气管堵塞器在华获批,是泰利福深耕中国市场、满足中国患者医疗需求的又一重要举措。未来,泰利福将继续优化其在中国的产品组合,为推动中国医疗健康事业的发展贡献更多力量。
About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in the world of healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.
At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, the Teleflex logo are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.
© 2025 Teleflex Incorporated. All rights reserved. MCC-2025-0101
Contacts:
Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investor.relations@teleflex.com
610-948-2836
Teleflex China
Yolanda Li (李婪)
Marketing Communications Supervisor (市场传播主管), China
yolanda.li@teleflex.com
+86 021 6060 6918
本文RSS来源:美通社
- 42名西藏新疆先心病患儿在上海德达心血管医院获"心"希望
- 信达生物口服小分子GLP-1R激动剂IBI3032的新药临床试验申请(IND)获美国FDA...
- Minaris Advanced Therapies开设了其新的最先进的GMP设施,以支持...
- 卓悦榜丨德达医疗荣膺"年度健康服务与智慧医疗最佳企业"奖项
- 仑卡奈单抗美国两年真实世界研究结果已在2025AAIC上进行展示
- "心火相传•智启未来" 欧姆龙健康医疗公益行柳州站,携手高校共育健康城市新力量
- 波士顿科学新一代左心耳封堵器WATCHMAN FLX Pro在华正式获批
- 护舒宝液体卫生巾Pro健康专研版全球首发,开启经期健康新时代
- CAS集成变革性的新AI功能
- 康宁杰瑞PD-L1/αvβ6双抗ADC创新药JSKN022临床试验申请获受理